Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000658860 | SCV000780657 | uncertain significance | not provided | 2017-12-01 | criteria provided, single submitter | clinical testing | |
Centogene AG - |
RCV001251185 | SCV001426543 | likely pathogenic | Tatton-Brown-Rahman overgrowth syndrome | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV001251185 | SCV004292063 | uncertain significance | Tatton-Brown-Rahman overgrowth syndrome | 2023-09-30 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 714 of the DNMT3A protein (p.Ser714Cys). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with clinical features of Tatton-Brown-Rahman syndrome (PMID: 28475857, 32860008). ClinVar contains an entry for this variant (Variation ID: 546858). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt DNMT3A protein function. Experimental studies have shown that this missense change affects DNMT3A function (PMID: 30705090, 31861499). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |